Holen Sie sich die Stockscreener-App
76.93
1.57%
-1.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$78.16
Offen:
$77.74
24-Stunden-Volumen:
3.63M
Relative Volume:
0.84
Marktkapitalisierung:
$45.17B
Einnahmen:
$5.69B
Nettoeinkommen (Verlust:
$4.14B
KGV:
11.05
EPS:
6.96
Netto-Cashflow:
$577.90M
1W Leistung:
-2.92%
1M Leistung:
-1.43%
6M Leistung:
+1.46%
1J Leistung:
+17.38%
1-Tages-Spanne:
$76.07
$78.04
1-Wochen-Bereich:
$76.07
$79.63
52-Wochen-Spanne:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
76.93 | 45.89B | 5.69B | 4.14B | 577.90M | 6.96 |
|
ABT
Abbott Laboratories
|
131.02 | 228.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.64 | 152.25B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
376.61 | 144.00B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.08 | 118.82B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
FTC Moves to Block Edwards Lifesciences’ $945 Million Acquisition of JenaValve Over Competition Concerns - MSN
FTC Sues to Block Edwards LifeSciences Medical Device Deal - MSN
FTC Sounds Alarm On Edwards’ Heart Device, M&A AttemptEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences Leads Heart Device Market With Value Upside - Finimize
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - MSN
Edwards Lifesciences’ ALT-FLOW II Trial: A Key Update for Heart Failure Treatment - TipRanks
Baird Adjusts Price Target on Edwards Lifesciences to $81 From $79, Maintains Neutral Rating - MarketScreener
FTC moves to block Edwards’ acquisition of JenaValve Technology - Medical Buyer
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve - WKZO
FTC sues to block Edwards Lifesciences' $945M JenaValve deal - Daily Journal
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
FTC sues to block Edwards Lifesciences purchase of JenaValve - MSN
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve | Business Information & News | FE - Westlaw Today
South Africa Advocacy Groups Push to Reopen Vertex Antitrust Probe - PYMNTS.com
FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal
Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex
FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times
Jenavalve disagrees with FTC's decision against proposed Edwards Lifesciences deal - MarketScreener
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition - Benzinga
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Edwards Lifesciences Fights FTC Block of JenaValve Deal as EPS Guidance Jumps to $2.55 - Stock Titan
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
Edwards Lifesciences Corporation's (NYSE:EW) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - Jammu Links News
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - Jammu Links News
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - Jammu Links News
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - Jammu Links News
How many analysts rate Edwards Lifesciences Corporation as a “Buy”Strongest growth potential - Jammu Links News
What are the technical indicators suggesting about Edwards Lifesciences CorporationMarket-crushing stock picks - Jammu Links News
Should I hold or sell Edwards Lifesciences Corporation stock in 2025Real Time Alerts For Fast Growth - Jammu Links News
Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair - TipRanks
Agree To Purchase Edwards Lifesciences At $65, Earn 5.2% Using Options - Nasdaq
How Edwards Lifesciences Corporation stock reacts to Fed policy changesAI Powered High Return Stock Calls Dominate Watchlists - beatles.ru
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here’s Why - Yahoo Finance
Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer? - TipRanks
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $84 to $100 - 富途牛牛
Edwards Lifesciences Stock (EW) Opinions on Q2 Earnings Beat - Quiver Quantitative
Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts upgrade Edwards as TAVR segment improves - MassDevice
BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com
Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent
Edwards Lifesciences Insider Makes a Major Stock Move! - TipRanks
Edwards Lifesciences Reports Strong Growth and Raises Guidance - TipRanks
Edwards Lifesciences debuts heart valve failure PSA as Rams training camp begins - Medical Marketing and Media
Edwards Lifesciences stock price target raised to $85 by Bernstein - Investing.com
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):